Evidence map›Paper›PMID 26702127›Full record

ArticleStem cells translational medicine2016

Controlled Dual Growth Factor Delivery From Microparticles Incorporated Within Human Bone Marrow-Derived Mesenchymal Stem Cell Aggregates for Enhanced Bone Tissue Engineering via Endochondral Ossification.

Phuong N Dang, Neha Dwivedi, Lauren M Phillips, Xiaohua Yu, Samuel Herberg, Caitlin Bowerman, Loran D Solorio, William L Murphy, Eben Alsberg

Open access · goldAbstract read
In one paragraph

Article in Stem cells translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 91 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Phuong N DangDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA.
Neha DwivediDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA.
Lauren M PhillipsDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA.
Xiaohua YuDepartment of Biomedical Engineering, University of Wisconsin, Madison, Wisconsin, USA.
Samuel HerbergDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA.
Caitlin BowermanDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA.
Loran D SolorioDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA.
William L MurphyDepartment of Biomedical Engineering, University of Wisconsin, Madison, Wisconsin, USA Department of Orthopedics and Rehabilitation, University of Wisconsin, Madison, Wisconsin, USA.
Eben AlsbergDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA Department of Orthopaedic Surgery, Case Western Reserve University, Cleveland, Ohio, USA eben.alsberg@case.edu.
Case Western Reserve University · USUniversity of Wisconsin–Madison · US

Funding

Driving Tissue Formation by Inductive Stem Cell Sheet TechnologyR01AR063194 · NIAMS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ALSBERG, EBEN · 2012 to 2016
$1.7M
Blockade of miR-29b-1-5p promotes MSC-mediated bone regeneration during agingF32DE024712 · NIDCR · CASE WESTERN RESERVE UNIVERSITY · PI HERBERG, SAMUEL · 2014 to 2016
$166k
NIAMS NIH HHS AR063194NIAMS NIH HHS R01 AR063194NIDCR NIH HHS DE024712NIDCR NIH HHS F32 DE024712
6 · The paper itself

Abstract

Bone tissue engineering via endochondral ossification has been explored by chondrogenically priming cells using soluble mediators for at least 3 weeks to produce a hypertrophic cartilage template. Although recapitulation of endochondral ossification has been achieved, long-term in vitro culture is required for priming cells through repeated supplementation of inductive factors in the media. To address this challenge, a microparticle-based growth factor delivery system was engineered to drive endochondral ossification within human bone marrow-derived mesenchymal stem cell (hMSC) aggregates. Sequential exogenous presentation of soluble transforming growth factor-β1 (TGF-β1) and bone morphogenetic protein-2 (BMP-2) at various defined time courses resulted in varying degrees of chondrogenesis and osteogenesis as demonstrated by glycosaminoglycan and calcium content. The time course that best induced endochondral ossification was used to guide the development of the microparticle-based controlled delivery system for TGF-β1 and BMP-2. Gelatin microparticles capable of relatively rapid release of TGF-β1 and mineral-coated hydroxyapatite microparticles permitting more sustained release of BMP-2 were then incorporated within hMSC aggregates and cultured for 5 weeks following the predetermined time course for sequential presentation of bioactive signals. Compared with cell-only aggregates treated with exogenous growth factors, aggregates with incorporated TGF-β1- and BMP-2-loaded microparticles exhibited enhanced chondrogenesis and alkaline phosphatase activity at week 2 and a greater degree of mineralization by week 5. Staining for types I and II collagen, osteopontin, and osteocalcin revealed the presence of cartilage and bone. This microparticle-incorporated system has potential as a readily implantable therapy for healing bone defects without the need for long-term in vitro chondrogenic priming. Significance: This study demonstrates the regulation of chondrogenesis and osteogenesis with regard to endochondral bone formation in high-density stem cell systems through the controlled presentation of inductive factors from incorporated microparticles. This work lays the foundation for a rapidly implantable tissue engineering system that promotes bone repair via endochondral ossification, a pathway that can delay the need for a functional vascular network and has an intrinsic ability to promote angiogenesis. The modular nature of this system lends well to using different cell types and/or growth factors to induce endochondral bone formation, as well as the production of other tissue types.

Indexed as

Alkaline PhosphataseBiomarkersBone Marrow CellsBone Morphogenetic Protein 2Calcification, PhysiologicCalciumCell AggregationChondrogenesisCollagen Type ICollagen Type IIDelayed-Action PreparationsDrug CompoundingDurapatiteGelatinGene ExpressionGlycosaminoglycansAlkaline PhosphataseBiomarkersBMP2 protein, humanBone Morphogenetic Protein 2CalciumCollagen Type ICollagen Type IIDelayed-Action PreparationsDurapatiteGelatinGlycosaminoglycansOsteocalcinOsteopontinTransforming Growth Factor beta1Adult human bone marrowBoneGrowth factor deliveryHigh-density cultureMesenchymal stem cellsTissue regeneration

Identifiers

PMID26702127
PMCPMC4729553
OpenAlexW2238333901

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.